Evidence map›Paper›PMID 35204557›Full record

ArticleDiagnostics (Basel, Switzerland)2022

The Adult Congenital Heart Disease Anatomic and Physiological Classification: Associations with Clinical Outcomes in Patients with Atrial Arrhythmias.

Anastasios Kartas, Andreas S Papazoglou, Diamantis Kosmidis, Dimitrios V Moysidis, Amalia Baroutidou, Ioannis Doundoulakis, Stefanos Despotopoulos, Elena Vrana, Athanasios Koutsakis, Georgios P Rampidis and 9 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03854149 (A Prospective, Observational, Multicenter Study on the Safety and Efficacy of Apixaban for the Prevention of Thromboembolism in Adults With Congenital Heart Disease and Atrial Arrhythmias), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03854149 completednot on this map

A Prospective, Observational, Multicenter Study on the Safety and Efficacy of Apixaban for the Prevention of Thromboembolism in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study

Typeobservational_patient_registrySponsorAHEPA University HospitalRan2019 to 2023Enrolled218ConditionsCongenital Heart Disease, Atrial Arrhythmia, Thromboembolism, Anticoagulants Causing Adverse Effects in Therapeutic Use
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Discovery ofBiology · 2023
    Article
  2. Article
  3. Identification ofDiagnostics (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Anastasios KartasFirst Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece.ORCID 0000-0002-1170-9133
Andreas S PapazoglouFirst Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece.ORCID 0000-0003-4981-8121
Diamantis KosmidisFirst Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece.
Dimitrios V MoysidisFirst Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece.
Amalia BaroutidouFirst Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece.ORCID 0000-0003-0182-8259
Ioannis DoundoulakisFirst Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece.ORCID 0000-0003-2184-3296
Stefanos DespotopoulosDepartment of Pediatric and Adult Congenital Heart Disease, Onassis Cardiac Surgery Center, 17674 Athens, Greece.
Elena VranaFirst Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece.ORCID 0000-0002-3477-1968
Athanasios KoutsakisFirst Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece.
Georgios P RampidisFirst Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece.ORCID 0000-0002-2452-6942
Despoina NtiloudiFirst Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece.
Sotiria LioriSecond Department of Cardiology, Attikon University Hospital, 12462 Athens, Greece.ORCID 0000-0003-4720-197X
Tereza MousiamaDepartment of Congenital Heart Disease, Mitera Childrens' Hospital, 15123 Athens, Greece.
Dimosthenis AvramidisDepartment of Congenital Heart Disease, Mitera Childrens' Hospital, 15123 Athens, Greece.ORCID 0000-0002-6100-7076
Sotiria ApostolopoulouDepartment of Pediatric and Adult Congenital Heart Disease, Onassis Cardiac Surgery Center, 17674 Athens, Greece.
Alexandra FrogoudakiSecond Department of Cardiology, Attikon University Hospital, 12462 Athens, Greece.
Afrodite TzifaDepartment of Congenital Heart Disease, Mitera Childrens' Hospital, 15123 Athens, Greece.
Haralambos KarvounisFirst Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece.
George GiannakoulasFirst Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece.ORCID 0000-0001-7491-6319
Aristotle University of Thessaloniki · GRMitera Hospital · GROnassis Cardiac Surgery Center · GRUniversity General Hospital Attikon · GR

Funding

Pfizer (United Kingdom) ERISTA, Reference Number: WI246683
6 · The paper itself

Abstract

The implications of the adult congenital heart disease anatomic and physiological classification (AP-ACHD) for risk assessment have not been adequately studied. A retrospective cohort study was conducted using data from an ongoing national, multicentre registry of patients with ACHD and atrial arrhythmias (AA) receiving apixaban (PROTECT-AR study, NCT03854149). At enrollment, patients were stratified according to Anatomic class (AnatC, range I to III) and physiological stage (PhyS, range B to D). A follow-up was conducted between May 2019 and September 2021. The primary outcome was a composite of death from any cause, any major thromboembolic event, major or clinically relevant non-major bleeding, or hospitalization. Cox proportional-hazards regression modeling was used to evaluate the risks for the outcome among AP-ACHD classes. Over a median 20-month follow-up period, 47 of 157 (29.9%) ACHD patients with AA experienced the composite outcome. Adjusted hazard ratios (aHR) with 95% confidence intervals (CI) for the outcome in PhyS C and PhyS D were 1.79 (95% CI 0.69 to 4.67) and 8.15 (95% CI 1.52 to 43.59), respectively, as compared with PhyS B. The corresponding aHRs in AnatC II and AnatC III were 1.12 (95% CI 0.37 to 3.41) and 1.06 (95% CI 0.24 to 4.63), respectively, as compared with AnatC I. In conclusion, the PhyS component of the AP-ACHD classification was an independent predictor of net adverse clinical events among ACHD patients with AA.

Indexed as

ACHDAP-ACHD classificationatrial arrhythmiacongenital heart diseasequality of lifeSF-36

Identifiers

PMID35204557
PMCPMC8870966
OpenAlexW4221055584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.